<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32814">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679469</url>
  </required_header>
  <id_info>
    <org_study_id>339-102-00003</org_study_id>
    <nct_id>NCT02679469</nct_id>
  </id_info>
  <brief_title>A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg
      in healthy Japanese male subjects will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of nalmefene</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the Maximum (peak) plasma concentration of the drug (Cmax)</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the Time to maximum (peak) plasma concentration (AUC)</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the Terminal-phase elimination half-life (T1/2)</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Date of informed consent to days 5 post-dose</time_frame>
    <description>Examinations: clinical safety laboratory tests, body weight, electrocardiograms (ECGs), vital signs, and physical examinations</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalmefene 10 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalmefene hydrochloride 10 mg</intervention_name>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is a Japanese male.

          -  The subject is able to read and understand the informed consent form (ICF).

          -  The subject has a body mass index (BMI) ≥ 19 kg/m2 and ≤ 25 kg/m2 at the screening
             visit.

          -  The subject has a resting pulse and heart rate (as read on the ECG) ≥ 45 bpm and ≤
             100 bpm at the screening visit.

        Exclusion Criteria:

          -  The subject has taken any prescription drugs, over-the counter medications, vitamin
             supplements, or supplements containing St. John's Wort (Hypericum perforatum) within
             2 weeks prior to Day 1.

          -  The subject has a significant history of alcohol abuse, defined as an alcohol intake
             greater than 21 units per week. (A unit of alcohol is defined as 250 mL of
             lager/beer, 100 mL of wine, or 25 mL of spirits.)

          -  The subject has taken any investigational products within 4 months prior to Day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-ichi Hashimoto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyusyu</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>January 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
